OverviewSuggest Edit

Hoth Therapeutics is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from indications such as atopic dermatitis. The Company also develops the BioLexa Platform, a product candidate intended to prevent the symptom-triggering flare-ups before they occur.

TypePublic
HQNew York, NY, US
Websitehoththerapeutics.com

Latest Updates

Employees (est.) (Feb 2020)2
Share Price (Jan 2021)$2.3 (+4%)
Cybersecurity ratingCMore

Hoth Therapeutics Office Locations

Hoth Therapeutics has an office in New York
New York, NY, US (HQ)
1 Rockefeller Plaza, 10th Floor
Show all (1)

Hoth Therapeutics Financials and Metrics

Hoth Therapeutics Revenue

USD

Net income (Q2, 2020)

(2.5m)

EBIT (Q2, 2020)

(2.5m)

Market capitalization (22-Jan-2021)

36.9m

Closing stock price (22-Jan-2021)

2.3

Cash (30-Jun-2020)

4.9m
Hoth Therapeutics's current market capitalization is $36.9 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

1.2m

R&D expense

586.8k785.3k2.0m

Operating expense total

1.9m785.3k2.0m

EBIT

(1.9m)(2.5m)(7.7m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

R&D expense

134.8k388.9k490.3k647.2k927.7k

Operating expense total

134.8k388.9k490.3k647.2k927.7k

EBIT

(829.4k)(1.3m)(1.7m)(1.8m)(2.5m)

Interest expense

4.4k
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

1.2m282.6k1.7m

Prepaid Expenses

12.4k110.1k

Current Assets

1.2m501.6k2.6m

PP&E

3.5k2.3k1.0k
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

1.5m737.7k5.2m4.1m3.2m4.3m4.9m

Prepaid Expenses

27.2k19.8k88.3k101.3k113.9k56.5k56.7k

Current Assets

1.5m757.5k5.3m4.2m4.1m4.9m7.0m

PP&E

2.9k2.6k2.0k1.7k1.4k738.0433.0
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(2.0m)(2.5m)(7.7m)

Depreciation and Amortization

188.01.2k1.2k

Accounts Payable

47.9k94.4k267.4k

Cash From Operating Activities

(465.2k)(2.1m)(4.9m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.7m)(1.9m)(829.4k)(2.1m)(3.8m)(1.8m)(4.3m)

Depreciation and Amortization

916.0302.0608.0916.0305.0610.0

Accounts Payable

1.5k(22.2k)(71.7k)65.0k(117.0k)113.7k(104.5k)

Cash From Operating Activities

(240.3k)(1.6m)(764.0k)(1.8m)(3.4m)(1.6m)(4.0m)
Show all financial metrics

Hoth Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Hoth Therapeutics Online and Social Media Presence

Embed Graph

Hoth Therapeutics News and Updates

Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for...

Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic...

Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S. Patent and Trademark Office (USPTO) has granted U.S....

Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)

NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the...

Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss

NEW YORK, March 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company' or "Hoth"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne as well...

Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

NEW YORK, Feb. 12, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment...
Show more

Hoth Therapeutics Blogs

HOTH THERAPEUTICS, INC. TO PRESENT AT THE THINKEQUITY CONFERENCE

NEW YORK, April 30, 2019 /PRNewswire/ — Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today annou…

Hoth Therapeutics Frequently Asked Questions

  • How many employees does Hoth Therapeutics have?

    Hoth Therapeutics has 2 employees.

  • Who are Hoth Therapeutics competitors?

    Competitors of Hoth Therapeutics include Alexion Pharmaceuticals, KiOmed Pharma and Veloxis Pharmaceuticals.

  • Where is Hoth Therapeutics headquarters?

    Hoth Therapeutics headquarters is located at 1 Rockefeller Plaza, 10th Floor, New York.

  • Where are Hoth Therapeutics offices?

    Hoth Therapeutics has an office in New York.

  • How many offices does Hoth Therapeutics have?

    Hoth Therapeutics has 1 office.